A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 19 Nov 2018 Planned End Date changed from 30 Jan 2020 to 30 Jun 2020.
- 19 Nov 2018 Planned primary completion date changed from 28 Feb 2019 to 30 Jun 2020.
- 19 Sep 2018 Planned End Date changed from 19 Dec 2019 to 28 Feb 2019.